With Christmas Day now just a fortnight away, it would not be a
surprise if much of the population found their pants becoming ever so
tighter in the coming weeks, as the high calorie content of festive
treats like mince pies, Christmas pudding and novelty chocolate foods
start to creep onto the waistline.
To further show this point, a 2011 survey conducted by MSN found that
the average Brit will consume two or three Christmas dinner servings on
the day itself, taking in 2,300 calories in the process. This equates
to a staggering 115% of the recommended daily intake for women and 92%
for men.
It seems a lot of people are worried
about the extra calories and are preparing for the possibility of weight
gain this year as Medical Specialists® Pharmacy have seen a massive
surge in the number of people coming to them seeking help with losing weight
and enquiring about the obesity treatments available such as Xenical
and Orlistat. Medical Specialists® have also witnessed a huge increase
in requests for treatment for conditions usually worsened by the cold
weather such as influenza and asthma.
However, it is still weight gain that remains as the primary worry
for much of the nation over the festive period, but there has been good
news this week for those trying to lose weight. It has emerged that
scientists in America are developing a pill that could help the body to
burn off excess fat and its creators even claim that “it could one day
replace the treadmill”.
Researchers based at Harvard University have found a way to trigger a
molecule that can convert ‘bad’ white fat cells into ‘good’ brown cells
that help to burn energy.
When a person consumes too many calories and doesn’t burn off a
sufficient amount, adult stem cells in the body start to generate a
higher amount of white fat cells, leading to a flabbier physique,
especially evident around the stomach and hips.
Brown fat cells on the other hand, are used by the body to burn
energy and produce heat. The colder the body becomes, the higher amount
of brown fat cells begin to get used up, and hence they are generally
easier to get rid of compared to the white cells. Not only this, but the
brown cells also work to reduce both the size and numbers of their
white counterparts.
Researchers say they have managed to pinpoint which molecule is
responsible for turning stem cells white or brown, and state that by
increasing the molecule, this will help the body to generate more brown
cells, instead of white.
Associate professor Chad Cowan, at Harvard, said: “What we were
really impressed by is that there are some compounds that have this same
kind of effect when they are administered to animals, but when you
remove them, the effect goes away.
“But what we saw here was a stable conversion of the white fat cells
to brown cells. You’re constantly replenishing your fat tissue so if you
were on a medication to convert the cells, each new fat cell would be
more metabolically active and would convert to brown fat over time.”
The scientists involved with the research go on to claim that this
decreases the risk of a person developing health conditions associated
with a fat build-up, such as type 2 diabetes.
A drug called tofacitinib, which helps to trigger the molecule for
cell conversion is actually already approved, but for the treatment of
rheumatoid arthritis. However, it remains to be seen exactly when a pill
for obesity that contains the molecule will be approved, with fears it
could damage the immune system.
Professor Cowan warned the compounds “target the same molecule, and that molecule plays a role in the inflammatory response”.
He stressed: “So if you administered them for a long time, the person
taking them could become immune compromised”, and his team added that
despite the fact any future obesity pill may help people to remain trim,
it would still not be a sufficient substitute for the other health
benefits to be gained from engaging in regular exercise.
Showing posts with label tofacitinib. Show all posts
Showing posts with label tofacitinib. Show all posts
Tuesday, 23 December 2014
Friday, 20 June 2014
Arthritis drug found to boost hair growth for alopecia sufferer
Male hair loss
is not a life-threatening condition. Nobody has ever died from losing
hair on the scalp, or indeed anywhere else around the body. However, it
is widely accepted that for some men, losing their hair can have massive
emotional and psychological damage.
One of the most common causes of hair loss is alopecia areata, an autoimmune disorder that typically causes round patches of rapid hair loss from some or even all areas of the body, but usually the scalp is the main area afflicted.
A more severe form of alopecia areata is known as alopecia universalis, whereby the sufferer unfortunately experiences total loss of all body hair. Perhaps the most well-known person to have alopecia universalis is comedian and star of Little Britain, Matt Lucas.
There remains no standard treatment or permanent cure for alopecia universalis, but experts have studied the possibilities of various treatments, such as immunomodulatory agents like imiquimod (the active ingredient in Aldara cream, used to treat genital warts).
However, doctors at Yale University in the U.S. have remarkably been able to reverse alopecia universalis in a 25-year-old unnamed male who also had plaque psoriasis. The man had initially requested help for his psoriasis, another autoimmune condition.
The doctors at Yale pondered if they could possibly treat both autoimmune problems with one single treatment, deciding to try the Pfizer-manufactured arthritis medication Xeljanz (tofacitinib citrate). This was chosen specifically as according to Science World Report, the drug had found to be effective in mice at treating both psoriasis and alopecia.
The patient was first administered with tofacitinib at 10mg daily by the doctors, and his psoriasis showed some improvement. However, he had also grown scalp and facial hair – the first hair he had grown in these areas for a staggering seven years.
After three more additional months of therapy, this time at a 15mg dose, the patient had benefited from a complete regrowth in scalp hair and quite visible eyebrows, eyelashes, and facial hair, as well as armpit and other hair, the doctors commented.
“The results are exactly what we hoped for,” said Brett A. King, M.D., senior author of the paper, published online in the Journal of Investigative Dermatology. “This is a huge step forward in the treatment of patients with this condition.”
“There are no good options for long-term treatment of alopecia universalis,” added King. “The best available science suggested this might work, and it has.”
According to King, scientists think the drug boosts hair growth by stopping the immune attack on hair follicles.
“By eight months there was full regrowth of hair,” said co-author Brittany G. Craiglow, M.D. “The patient has reported feeling no side effects, and we’ve seen no lab test abnormalities, either.”
One of the most common causes of hair loss is alopecia areata, an autoimmune disorder that typically causes round patches of rapid hair loss from some or even all areas of the body, but usually the scalp is the main area afflicted.
A more severe form of alopecia areata is known as alopecia universalis, whereby the sufferer unfortunately experiences total loss of all body hair. Perhaps the most well-known person to have alopecia universalis is comedian and star of Little Britain, Matt Lucas.
There remains no standard treatment or permanent cure for alopecia universalis, but experts have studied the possibilities of various treatments, such as immunomodulatory agents like imiquimod (the active ingredient in Aldara cream, used to treat genital warts).
However, doctors at Yale University in the U.S. have remarkably been able to reverse alopecia universalis in a 25-year-old unnamed male who also had plaque psoriasis. The man had initially requested help for his psoriasis, another autoimmune condition.
The doctors at Yale pondered if they could possibly treat both autoimmune problems with one single treatment, deciding to try the Pfizer-manufactured arthritis medication Xeljanz (tofacitinib citrate). This was chosen specifically as according to Science World Report, the drug had found to be effective in mice at treating both psoriasis and alopecia.
The patient was first administered with tofacitinib at 10mg daily by the doctors, and his psoriasis showed some improvement. However, he had also grown scalp and facial hair – the first hair he had grown in these areas for a staggering seven years.
After three more additional months of therapy, this time at a 15mg dose, the patient had benefited from a complete regrowth in scalp hair and quite visible eyebrows, eyelashes, and facial hair, as well as armpit and other hair, the doctors commented.
“The results are exactly what we hoped for,” said Brett A. King, M.D., senior author of the paper, published online in the Journal of Investigative Dermatology. “This is a huge step forward in the treatment of patients with this condition.”
“There are no good options for long-term treatment of alopecia universalis,” added King. “The best available science suggested this might work, and it has.”
According to King, scientists think the drug boosts hair growth by stopping the immune attack on hair follicles.
“By eight months there was full regrowth of hair,” said co-author Brittany G. Craiglow, M.D. “The patient has reported feeling no side effects, and we’ve seen no lab test abnormalities, either.”
Subscribe to:
Posts (Atom)

